340B Drug Pricing Program
The American Hospital Association (AHA) writes to alert you to the latest development in connection with the growing number of drug company policies requiring covered entities to submit onerous amounts of claims data in exchange for their statutorily owed 340B discounts.
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B Drug Pricing Program. The letter states:
The House Committee on Ways and Means, on April 28 at 10 a.m. ET, will host a hearing during which hospital and health system leaders are expected to testify on
health care affordability.
Washington Post publishes AHA letter in response to anti-340B editorial
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind is flawed in both conception and design,” the AHA told the agency today. Responding to a request for information, the AHA shared…
AHA Comments on 340B Rebate Model RFI.
The AHA responds to the Health Resources and Services Administration’s (HRSA) Request for Information regarding a potential 340B Rebate Model Pilot Program.
AHA responds to Washington Post editorial on 340B program.
AHA Seeks En Banc review of 4th Circuit 340B ruling.
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that invalidated West Virginia’s law protecting 340B contract pharmacy arrangements.